ROCKWELL MEDICAL INC RMTI
ASignal's systematic analysis rates RMTI as Neutral.
Reflects the latest available analysis · analyzed Nov 7, 2026
The case on RMTI
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive price momentum indicating short-term uptrend
- Free cash flow generation despite net losses
- Strong liquidity position with current ratio of 3.25x
- Low debt-to-equity ratio of 0.40x providing financial flexibility
- MACD histogram expanding above signal line suggesting bullish momentum
- Negative return on equity (-15.53%) indicating poor capital efficiency
- Negative operating and net margins reflecting unprofitability
- High forward P/E of 110.43x suggesting elevated valuation risk
- PEG ratio of 4.43x indicating overvaluation relative to growth
- EV/EBITDA at -8.35x due to negative EBITDA
See the full verdict on RMTI
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RMTI
Most investors never get a second opinion, let alone several. ASignal runs RMTI past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.